Literature DB >> 8373457

Gangliosides and neurological diseases.

J S Schneider, D P Roeltgen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8373457      PMCID： PMC1676609          DOI： 10.1136/bmj.306.6871.204-a

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

Review 1.  Critical review of gangliosides and thyrotropin-releasing hormone in peripheral neuromuscular diseases.

Authors:  W G Bradley
Journal:  Muscle Nerve       Date:  1990-09       Impact factor: 3.217

2.  Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.

Authors:  J S Schneider; A Pope; K Simpson; J Taggart; M G Smith; L DiStefano
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

3.  Gangliosides and neurological diseases.

Authors:  P O Behan; B A Haniffah
Journal:  BMJ       Date:  1992-11-28

4.  Bovine gangliosides and acute motor polyneuropathy.

Authors:  A Figueras; F J Morales-Olivas; D Capellà; V Palop; J R Laporte
Journal:  BMJ       Date:  1992-11-28

5.  GM1 ganglioside treatment promotes recovery of striatal dopamine concentrations in the mouse model of MPTP-induced parkinsonism.

Authors:  J S Schneider; A Yuwiler
Journal:  Exp Neurol       Date:  1989-08       Impact factor: 5.330

6.  Ganglioside GM1 prevents death induced by excessive excitatory neurotransmission in cultured hippocampal pyramidal neurons.

Authors:  S D Skaper; A Leon; L Facci
Journal:  Neurosci Lett       Date:  1991-05-13       Impact factor: 3.046
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.